ORCA Therapeutics to Present Clinical Data on ORCA-010 at International Oncolytic Virus Conference

Amsterdam, The Netherlands – October 2024

ORCA Therapeutics B.V., a Dutch biopharmaceutical company pioneering innovative oncolytic neo-adjuvant immunotherapies for cancer treatment, today announced that Prof. Dr. Victor van Beusechem will present new clinical data from the company’s lead product ORCA-010 at the International Oncolytic Virus Conference (IOVC) in Rotterdam.

The presentation, titled “Oncolytic adenovirus ORCA-010 activates the tumor immune microenvironment and induces systemic tumor-specific T cell responses in patients with newly-diagnosed prostate cancer,” will highlight key findings from the ongoing Phase I/IIA clinical trial. Post-treatment analyses of radical prostatectomy specimens revealed notably low tumor presence in two patients compared to typical observations in untreated prostates and other treated patients in the study, suggesting potential treatment effect. This observation is further supported by one-year follow-up prostate biopsies in patients who did not undergo prostatectomy. Additionally, all other patients demonstrated evidence of an ongoing anti-tumor immune response in the prostate.

“We are pleased to share these important clinical insights about ORCA-010’s mechanism of action in prostate cancer,” said Prof. Dr. van Beusechem. “The post-treatment tissue analyses provide interesting observations regarding ORCA-010’s effects on the tumor microenvironment and its ability to generate systemic tumor-specific T cell responses. These findings support the continued development of ORCA-010 as a potential new treatment option for prostate cancer patients.”

About ORCA-010

ORCA-010 is a state-of-the-art oncolytic adenovirus therapy designed to modify the tumor microenvironment while inducing anti-tumor immune responses. The ongoing Phase I/IIA trial focuses on treatment-naïve, early-stage prostate cancer patients. Initial analyses suggest immunological activity in the tumor microenvironment, supporting ORCA-010’s continued investigation as a potential treatment approach for prostate cancer.

About ORCA Therapeutics BV

ORCA Therapeutics BV is a leader in potent neo-adjuvant immuno-oncology therapeutics, specializing in oncolytic viruses and innovative gene therapy approaches. The company is dedicated to translating cutting-edge scientific discoveries into effective therapeutic solutions, addressing unmet medical needs and improving patient outcomes globally.

For more information about our mission and ongoing projects, visit http://www.orca-therapeutics.com

Media Contact

Dr. Wenliang Dong, Ph.D., MBA
CEO, ORCA Therapeutics BV
Email: info@orca-therapeutics.com
Website: www.orca-therapeutics.com